Schering patents expiration
1. Noxafil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5703079 | SCHERING | Tetrahydrofuran antifungals |
Aug, 2014
(9 years ago) | |
| US6958337 | SCHERING | Crystalline antifungal polymorph |
Oct, 2018
(5 years ago) | |
| US5661151 | SCHERING | Tetrahydrofuran antifungals |
Jul, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263600 | SCHERING | Antifungal composition with enhanced bioavailability |
Apr, 2022
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2011 |
Drugs and Companies using POSACONAZOLE ingredient
NCE-1 date: 15 September, 2010
Market Authorisation Date: 15 September, 2006
Treatment: Prophylaxis of invasive aspergillus and candida infections and treatment of oropharyngeal candidiasis
Dosage: SUSPENSION;ORAL
NOXAFIL family patents
2. Rebetol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6461605 | SCHERING | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(7 years ago) | |
| US6524570 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
| US6177074 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
|
US6177074 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(6 years ago) | |
|
US6524570 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(6 years ago) | |
|
US6461605 (Pediatric) | SCHERING | Continuous low-dose cytokine infusion therapy |
May, 2017
(6 years ago) | |
| US6472373 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(6 years ago) | |
| US6172046 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(6 years ago) | |
|
US6172046 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(6 years ago) | |
|
US6472373 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(6 years ago) | |
| US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(1 year, 16 days ago) | |
|
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(6 months ago) | |
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Treatment: Method of using ribavirin in combination with intron a (interferon alpha-2 b recombinant) injection to treat patients with chronic hepatitis c; Method of using ribavirin in combination with pegylated ...
Dosage: SOLUTION;ORAL
REBETOL family patents